Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Brandi Fontenot

Hospitalist Baton Rouge, LA Medical Doctor

NPI 1770882656 CMS profile 584619

5000 Hennessy Blvd, Baton Rouge, LA 70808

Open in the dashboard

General payments

$1,981

141 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Brandi Fontenot of Baton Rouge, LA is reported in the CMS Open Payments database as having received $1,981 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $84 5
2022 General $514 30
2021 General $854 68
2020 General $314 22
2019 General $215 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandi Fontenot
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Brandi Fontenot were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Brandi Fontenot Hospitalist median Middle half National median
2019 $215 $96 $28–$201 $163
2020 $314 $48 $19–$125 $114
2021 $854 $70 $23–$167 $132
2022 $514 $85 $27–$174 $149
2023 $84 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $643 44 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $248 21 payments
  3. Pfizer Inc. $198 13 payments
  4. Amarin Pharma Inc. $194 13 payments
  5. AbbVie, Inc. $133 12 payments
  6. Novartis Pharmaceuticals Corporation $119 7 payments
  7. GlaxoSmithKline, LLC. $109 8 payments
  8. Novo Nordisk Inc $47 3 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $35 2 payments
  10. Jazz Pharmaceuticals Inc. $32 2 payments
  11. Other $223 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,977 140 payments
  2. Education $4 1 payment
Products named General payments · program years 2019–2023
  1. CYCLOSET $598 41 payments
  2. Vascepa $183 12 payments
  3. VYVANSE $137 14 payments
  4. COLOGUARD DNA CAPTURE REAGENTS $115 8 payments
  5. VRAYLAR $86 8 payments
  6. ENTRESTO $84 5 payments
  7. TRELEGY ELLIPTA $81 6 payments
  8. COLOGUARD $71 4 payments
  9. REYVOW $62 4 payments
  10. ELIQUIS $50 4 payments
  11. Other $862 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

1,176

Median for Internal Medicine: 777

Drug cost

$115,142

Median for Internal Medicine: $73,373

Branded share of claims

21.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 33 $41,266
Trulicity Dulaglutide Brand 18 $23,199
Ozempic Semaglutide Brand 24 $22,245
Jardiance Empagliflozin Brand 11 $15,968
Gabapentin Generic 45 $706
Azelastine Hcl Generic 24 $679
Valacyclovir Valacyclovir Hcl Brand 15 $622
Albuterol Sulfate Hfa Albuterol Sulfate Brand 22 $615
Levothyroxine Sodium Generic 60 $573
Omeprazole Generic 36 $541

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$4,734

Medicare's payments for the services billed

Medicare patients

40

Average age 67

Services billed

77

29 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 38%
Arthritis 30%
Depression 28%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record